The company added in a statement that these approvals pave
the way for the plant to commence operations in the first quarter of 2026.
At the same time, EIPICO announced the official commercial
launch of its new biologic product, Adalimumab. The supply of this product has
been awarded to the Unified Procurement Authority to ensure it reaches the
widest possible segment of patients in need.
Adalimumab is a high-tech medication used to treat a range
of autoimmune and chronic inflammatory diseases. It provides effective relief
from pain and swelling, reduces joint damage, and slows disease progression.
The drug also offers long-term inflammation control,
contributing to improved quality of life and daily functioning for patients. It
has been designed to ensure ease of use and efficient adherence to treatment.
EIPICO confirmed that it has received an official order to
export Adalimumab to Namibia, highlighting the confidence of international
markets in the company’s product quality and demonstrating its ability to
access new markets within the African continent. This represents an important
addition to the company’s growth and expansion in exports.